Abstract:BACKGROUND:Despite recent reforms, distorting funding mechanisms and over-prescribing still maintain severe financial barriers to medicines access in China. Complicated and interrelated problems in the pharmaceutical sector require a common framework to be resolved as fragmented solutions do not work. We present a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and propose policy recommendations for promoting universal access to medicines in China.METHODS:Drawing on multiple sources of information, including a review of published literatures and official national data, field investigations in six provinces and interviews with key opinion leaders, this paper presents a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and proposes policy recommendations for promoting universal access to medicines in China.RESULTS:Public expenditure on medicines has been strictly controlled since the national healthcare reforms of 2009. Yet total pharmaceutical expenditure (TPE) and total health expenditure growth rates continuously outpaced the growth of gross domestic product (GDP). With 2.4% of GDP, TPE now exceeds that of most high income countries. The distorted provider and consumer incentives in the Chinese health system have not fundamentally changed. Price-setting and reimbursement mechanisms do not promote cost-effective use of medicines. Inappropriate price controls and perverse financial incentives are the un-resolved root causes of preference of originator brands for some major diseases and shortages of low-cost and low-consumption medicines. In addition, access to expensive life-saving medicines is yet systematically addressed.CONCLUSIONS:The complicated and interdependent problems interact in a way that leads to significant system problems in China, which create dual challenges that both the developing country and the developed countries are facing. To further promote access to medicines, China should speed up the re-assessment of the quality and efficacy of domestically produced generic medicines; coordinate various reforms of price determination, insurance payments, and procurement policies; address medicine shortages through comprehensive policies and legislation; establish specific mechanisms to achieve sustainable equitable access to expensive essential medicines with health technology assessment as a tool to ensure that policy and priority setting are created in a coherent and evidence-based way.

Zero mark-up policy of essential medicines system in China:Problems and recommendations

Essential medicine policy in China: pros and cons.

Essential medicines system reform in China:Achievements and challenges

Can zero-markup policy for drug sales in public hospitals resolve the problem of ‘seeing a doctor is too expensive’ in China? A case study of four municipal general tertiary hospitals at H City in Z Province

A Review of Promoting Access to Medicines in China - Problems and Recommendations.

Strategies and policy recommendations on improving essential medicines system in China

The Existing Problems and Countermeasures of Implementing the Essential Drugs System

Evaluation on the Key Policy Issues of Zero Out-of-pocket Program Implementation of Essential Medicines System in Hangzhou

A Survey of Availability, Price and Affordability of Essential Medicines from 2011 to 2016 in Chinese Secondary and Tertiary Hospitals

An Analysis on Rational Use and Affordability of Medicine after the Implementation of National Essential Medicines Policy and Zero Mark-up Policy in Hangzhou, China

Preliminary analysis of pharmaceuticals zero mark-up policy in Shanghai

Small-scale or Full-Scale? the Zero Mark-Up Drug Policy in China

National Essential Drug Policy:Status Quo and Countermeasure

Consideration and Discussion of the Establishment and Improvement of Essential Medicine Financing Mechanism

Policy analysis on ensuring production and supply of fewer essential medicines: Based on the theory of generator behavior

Analysis on the Impacts of the Essential Medicines System on Primary Health Institutions in Shaanxi Province: Based on a Sample Survey of 4 Primary Health Institutions in 2 Counties

Problems and Reform Strategies of Medicines Distribution System in China

Analysis of the Implementation Status of Zero Slip Policy of Essential Drugs in Basic Medical and Health Institutions

Investigation of the Availability and Accessibility of Essential Drugs Based on Experience Abroad

Short-term differences in drug prices after implementation of the national essential medicines system: A case study in rural Jiangxi Province, China

Intended and Unintended Consequences of China’s Zero Markup Drug Policy